HIV-Associated Neurocognitive Disorders: Molecular and Cellular Mechanisms and Clinical Manifestations is a comprehensive volume on the field of HIV-Associated Neurocognitive Disorders (HAND) as well as its associated comorbidities. Covering clinical manifestations as well as molecular and cellular mechanisms, this book discusses available macaque and rodent animal models of HAND, epigenetic regulation, and signaling pathways underlying symptoms. Chapters also cover prevention and therapeutic strategies, as well as diagnosis and biomarkers associated with disease outcomes. This volume is appropriate for basic research and clinical investigators working in the area of HIV-1 infection.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors - p. xv 7. The neuroHIV journey - p. xxi 8. Preface - p. xxiii 9. Chapter 1. An overview of the mechanisms of HIV-1 infection, latency, pathogenesis, and eradication strategies from the CNS - p. 1 10. Chapter 2. Central nervous system complications of human immunodeficiency virus infection - p. 23 11. Chapter 3. Health literacy in HIV-associated neurocognitive disorders - p. 45 12. Chapter 4. Neuroimaging insights into the CNS effects of HIV infection - p. 57 13. Chapter 5. Endolysosome iron: Early and upstream subcellular organellar events associated with HAND - p. 69 14. Chapter 6. White matter loss and oligodendrocyte dysfunction in HAND - p. 81 15. Chapter 7. Pathogenesis of HIV-associated pain - p. 95 16. Chapter 8. Neuropathogenesis of HIV-associated neuropathic pain - p. 117 17. Chapter 9. Neuropathic pain in HIV and the role of the autophagy pathway - p. 135 18. Chapter 10. Host peripheral immune dynamics increase HIV-associated neurocognitive disorders incidence and progression - p. 147 19. Chapter 11. The role of immunometabolism in HIV-associated depression and cognitive impairment - p. 161 20. Chapter 12. Role of extracellular viral regulatory proteins in neuropathogenesis - p. 179 21. Chapter 13. Role of inflammasomes in HIV-1 and drug abuse-mediated neuroinflammation - p. 209 22. Chapter 14. The contribution of myeloid cells to HIV neuropathogenesis - p. 225 23. Chapter 15. Immunophilin ligands modulate phagocytosis and viral replication in HIV-infected macrophages - p. 239 24. Chapter 16. Immunometabolic mechanisms of HIV-associated neurocognitive disorders and traumatic brain injury: Commonalities and contrasts between chronic and acute neurodegenerative pathologies - p. 245 25. Chapter 17. Endolysosome dysfunction in HAND - p. 271 26. Chapter 18. Evolving biomarkers for HIV-associated neurocognitive disorders (HAND) - p. 295 27. Chapter 19. Intracellular innate immunity against HIV-1 infection - p. 307 28. Chapter 20. NeuroHIV and the glymphatic system - p. 313 29. Chapter 21. The p75 neurotrophin receptor: Emerging role in the pathogenesis of mature synapses in human immunodeficiency virus–associated neurocognitive disorders - p. 323 30. Chapter 22. The role of HIV-associated neuroendocrine dysfunction in HAND - p. 341 31. Chapter 23. Impact of SARS-CoV-2/COVID-19 on HIV-1-associated neurocognitive disorders - p. 355 32. Chapter 24. Molecular mechanisms of dopaminergic transmission in NeuroHIV - p. 379 33. Chapter 25. The effect of substance misuse on HIV persistence in the CNS: Epidemiological, immunological, and molecular considerations - p. 399 34. Chapter 26. Extracellular vesicles in alcohol and tobacco-induced NeuroAIDS - p. 439 35. Chapter 27. NeuroHIV in the context of opioid use disorder: a complex and evolving relationship - p. 459 36. Chapter 28. Impairment of cholesterol homeostasis induced by Nef-containing extracellular vesicles as a factor in HAND pathogenesis - p. 479 37. Chapter 29. Long noncoding RNAs in immune response, viral infection, and opioid use - p. 487 38. Chapter 30. Using cross-species behavioral tools to determine mechanisms contributing to HIV-associated neurocognitive disorder and comorbid substance use - p. 503 39. Chapter 31. Therapeutic potential of curcumin in HIV-1-associated neurocognitive disorders - p. 525 40. Chapter 32. Targeting the endocannabinoid system in HAND - p. 539 41. Chapter 33. Predicting the effectiveness of combination treatment of dolutegravir and fluoxetine for depressive disorders in HIV - p. 557 42. Chapter 34. Antiretroviral therapy and its cerebral vascular toxicity - p. 567 43. Chapter 35. Strategies for HIV-1 elimination - p. 595 44. Index - p. 619
HIV-Associated Neurocognitive Disorders: Molecular and Cellular Mechanisms and Clinical Manifestations is a comprehensive volume on the field of HIV-Associated Neurocognitive Disorders (HAND) as well as its associated comorbidities. Covering clinical manifestations as well as molecular and cellular mechanisms, this book discusses available macaque and rodent animal models of HAND, epigenetic regulation, and signaling pathways underlying symptoms. Chapters also cover prevention and therapeutic strategies, as well as diagnosis and biomarkers associated with disease outcomes. This volume is appropriate for basic research and clinical investigators working in the area of HIV-1 infection.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Contributors - p. xv 7. The neuroHIV journey - p. xxi 8. Preface - p. xxiii 9. Chapter 1. An overview of the mechanisms of HIV-1 infection, latency, pathogenesis, and eradication strategies from the CNS - p. 1 10. Chapter 2. Central nervous system complications of human immunodeficiency virus infection - p. 23 11. Chapter 3. Health literacy in HIV-associated neurocognitive disorders - p. 45 12. Chapter 4. Neuroimaging insights into the CNS effects of HIV infection - p. 57 13. Chapter 5. Endolysosome iron: Early and upstream subcellular organellar events associated with HAND - p. 69 14. Chapter 6. White matter loss and oligodendrocyte dysfunction in HAND - p. 81 15. Chapter 7. Pathogenesis of HIV-associated pain - p. 95 16. Chapter 8. Neuropathogenesis of HIV-associated neuropathic pain - p. 117 17. Chapter 9. Neuropathic pain in HIV and the role of the autophagy pathway - p. 135 18. Chapter 10. Host peripheral immune dynamics increase HIV-associated neurocognitive disorders incidence and progression - p. 147 19. Chapter 11. The role of immunometabolism in HIV-associated depression and cognitive impairment - p. 161 20. Chapter 12. Role of extracellular viral regulatory proteins in neuropathogenesis - p. 179 21. Chapter 13. Role of inflammasomes in HIV-1 and drug abuse-mediated neuroinflammation - p. 209 22. Chapter 14. The contribution of myeloid cells to HIV neuropathogenesis - p. 225 23. Chapter 15. Immunophilin ligands modulate phagocytosis and viral replication in HIV-infected macrophages - p. 239 24. Chapter 16. Immunometabolic mechanisms of HIV-associated neurocognitive disorders and traumatic brain injury: Commonalities and contrasts between chronic and acute neurodegenerative pathologies - p. 245 25. Chapter 17. Endolysosome dysfunction in HAND - p. 271 26. Chapter 18. Evolving biomarkers for HIV-associated neurocognitive disorders (HAND) - p. 295 27. Chapter 19. Intracellular innate immunity against HIV-1 infection - p. 307 28. Chapter 20. NeuroHIV and the glymphatic system - p. 313 29. Chapter 21. The p75 neurotrophin receptor: Emerging role in the pathogenesis of mature synapses in human immunodeficiency virus–associated neurocognitive disorders - p. 323 30. Chapter 22. The role of HIV-associated neuroendocrine dysfunction in HAND - p. 341 31. Chapter 23. Impact of SARS-CoV-2/COVID-19 on HIV-1-associated neurocognitive disorders - p. 355 32. Chapter 24. Molecular mechanisms of dopaminergic transmission in NeuroHIV - p. 379 33. Chapter 25. The effect of substance misuse on HIV persistence in the CNS: Epidemiological, immunological, and molecular considerations - p. 399 34. Chapter 26. Extracellular vesicles in alcohol and tobacco-induced NeuroAIDS - p. 439 35. Chapter 27. NeuroHIV in the context of opioid use disorder: a complex and evolving relationship - p. 459 36. Chapter 28. Impairment of cholesterol homeostasis induced by Nef-containing extracellular vesicles as a factor in HAND pathogenesis - p. 479 37. Chapter 29. Long noncoding RNAs in immune response, viral infection, and opioid use - p. 487 38. Chapter 30. Using cross-species behavioral tools to determine mechanisms contributing to HIV-associated neurocognitive disorder and comorbid substance use - p. 503 39. Chapter 31. Therapeutic potential of curcumin in HIV-1-associated neurocognitive disorders - p. 525 40. Chapter 32. Targeting the endocannabinoid system in HAND - p. 539 41. Chapter 33. Predicting the effectiveness of combination treatment of dolutegravir and fluoxetine for depressive disorders in HIV - p. 557 42. Chapter 34. Antiretroviral therapy and its cerebral vascular toxicity - p. 567 43. Chapter 35. Strategies for HIV-1 elimination - p. 595 44. Index - p. 619
